• The new center will be a hub for both Roche and Genentech, bringing together expertise in Cardiovascular, Renal, and Metabolism, as well as for data science and AI specialists to drive innovation in drug discovery and development
• Roche will be the first to join Harvard’s Enterprise Research Campus in Allston, taking a suite in the first phase of the project’s cutting-edge lab space
• Starting with a lease of 30’000 square feet, Roche intends to invest over the coming years into a research and development presence with eventually up to 500 employees
• Roche has long standing partnerships with Harvard University and others in the region and the center will expand Roche’s and Genentech’s presence in the vibrant Boston healthcare ecosystem

Basel, March 7, 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston which will further strengthen the long-standing partnership in areas such as disease biology, engineering, and artificial intelligence / machine learning.

The Roche Genentech Innovation Center Boston will serve as Roche’s Cardiovascular, Renal, and Metabolism (CVRM) hub, establishing a significant end-to-end R&D presence in CVRM. It will also support some of Roche’s and Genentech’s efforts in AI and data science to accelerate drug discovery and development. The laboratories will be equipped for advanced research, and over time the center could employ up to 500 people. Manu Chakravarthy, SVP and Global Head of CVRM Product Development, will be the center’s sit…